{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:14:03Z","timestamp":1789661643076,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune encephalitis (AE) poses significant challenges in clinical management, requiring effective monitoring tools for therapeutic success and relapse detection. This study aims to assess the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) as compared to the modified Rankin scale (mRS) in evaluating AE patients and to determine the real-world adoption of the CASE score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted on 20 AE patients, assessing clinical data including symptomatology, diagnostic findings, and therapeutic regimens. Furthermore, we performed a systematic review on the test performance criteria and the real-world use of the CASE score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The CASE score showed a higher sensitivity in detecting clinical changes compared to the mRS, with a significant correlation between the two scales throughout the disease course (r\u2009=\u20090.85, p\u2009&lt;\u20090.01). A systematic review of 150 articles revealed widespread adoption of the CASE score, especially in Asian populations, demonstrating high reliability and internal consistency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite limitations such as retrospective design and small sample size, our findings underscore the CASE score's utility in both clinical practice and research settings. The CASE score emerges as a valuable tool for monitoring AE patients, offering improved sensitivity over existing scales like the mRS. Further validation studies in diverse populations are warranted to establish its broader applicability and inform future therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-024-07642-1","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:02:16Z","timestamp":1718110936000},"page":"5423-5428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of the clinical assessment scale for autoimmune encephalitis (CASE) in a retrospective cohort and a systematic review"],"prefix":"10.1007","volume":"45","author":[{"given":"Eva","family":"Soellradl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"von Oertzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-6821","authenticated-orcid":false,"given":"Judith N.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"key":"7642_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau J, T\u00fcz\u00fcn E, Wu H et al (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25\u201336. https:\/\/doi.org\/10.1002\/ana.21050","journal-title":"Ann Neurol"},{"key":"7642_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/brain\/awx323","volume":"141","author":"J Thompson","year":"2018","unstructured":"Thompson J, Bi M, Murchison AG et al (2018) The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141:348\u2013356. https:\/\/doi.org\/10.1093\/brain\/awx323","journal-title":"Brain"},{"key":"7642_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1756285616656295","volume":"9","author":"D Dubey","year":"2016","unstructured":"Dubey D, Farzal Z, Hays R et al (2016) Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis. Ther Adv Neurol Disord 9:369\u2013377. https:\/\/doi.org\/10.1177\/1756285616656295","journal-title":"Ther Adv Neurol Disord"},{"key":"7642_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.str.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604\u2013607. https:\/\/doi.org\/10.1161\/01.str.19.5.604","journal-title":"Stroke"},{"key":"7642_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ana.25421","volume":"85","author":"J-A Lim","year":"2019","unstructured":"Lim J-A, Lee S-T, Moon J et al (2019) Development of the clinical assessment scale in autoimmune encephalitis. Ann Neurol 85:352\u2013358. https:\/\/doi.org\/10.1002\/ana.25421","journal-title":"Ann Neurol"},{"key":"7642_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391\u2013404. https:\/\/doi.org\/10.1016\/S1474-4422(15)00401-9","journal-title":"Lancet Neurol"},{"key":"7642_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40120-021-00278-9","volume":"10","author":"M-T Cai","year":"2021","unstructured":"Cai M-T, Lai Q-L, Zheng Y et al (2021) Validation of the Clinical Assessment Scale for Autoimmune Encephalitis: A Multicenter Study. Neurol Ther 10:985\u20131000. https:\/\/doi.org\/10.1007\/s40120-021-00278-9","journal-title":"Neurol Ther"},{"key":"7642_CR8","doi-asserted-by":"publisher","first-page":"796965","DOI":"10.3389\/fimmu.2021.796965","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tu E, Yao C et al (2021) Validation of the Clinical Assessment Scale in Autoimmune Encephalitis in Chinese Patients. Front Immunol 12:796965. https:\/\/doi.org\/10.3389\/fimmu.2021.796965","journal-title":"Front Immunol"},{"key":"7642_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.braindev.2022.09.009","volume":"45","author":"PK Panda","year":"2023","unstructured":"Panda PK, Sharawat IK, Ramachandran A et al (2023) Validity and prognostic utility of clinical assessment scale for autoimmune encephalitis (CASE) score in children with autoimmune encephalitis. Brain Dev 45:8\u201315. https:\/\/doi.org\/10.1016\/j.braindev.2022.09.009","journal-title":"Brain Dev"},{"key":"7642_CR10","doi-asserted-by":"publisher","first-page":"915352","DOI":"10.3389\/fimmu.2022.915352","volume":"13","author":"H Zhou","year":"2022","unstructured":"Zhou H, Deng Q, Yang Z et al (2022) Performance of the clinical assessment scale for autoimmune encephalitis in a pediatric autoimmune encephalitis cohort. Front Immunol 13:915352. https:\/\/doi.org\/10.3389\/fimmu.2022.915352","journal-title":"Front Immunol"},{"key":"7642_CR11","doi-asserted-by":"publisher","first-page":"e200178","DOI":"10.1212\/NXI.0000000000200178","volume":"11","author":"A Aboseif","year":"2024","unstructured":"Aboseif A, Li Y, Amin M et al (2024) Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune Encephalitis. Neurol Neuroimmunol Neuroinflamm 11:e200178. https:\/\/doi.org\/10.1212\/NXI.0000000000200178","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7642_CR12","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1002\/acn3.51865","volume":"10","author":"S Macher","year":"2023","unstructured":"Macher S, Bsteh G, H\u00f6ftberger R et al (2023) Clinical scales in autoimmune encephalitis-A retrospective monocentric cohort study. Ann Clin Transl Neurol 10:1768\u20131775. https:\/\/doi.org\/10.1002\/acn3.51865","journal-title":"Ann Clin Transl Neurol"},{"key":"7642_CR13","doi-asserted-by":"publisher","first-page":"578203","DOI":"10.1016\/j.jneuroim.2023.578203","volume":"383","author":"X Cheng","year":"2023","unstructured":"Cheng X, Li Y, Wang Y et al (2023) Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis. J Neuroimmunol 383:578203. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578203","journal-title":"J Neuroimmunol"},{"key":"7642_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.10.014","volume":"96","author":"J Broadley","year":"2019","unstructured":"Broadley J, Seneviratne U, Beech P et al (2019) Prognosticating autoimmune encephalitis: A systematic review. J Autoimmun 96:24\u201334. https:\/\/doi.org\/10.1016\/j.jaut.2018.10.014","journal-title":"J Autoimmun"},{"key":"7642_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/brainsci12010004","volume":"12","author":"M-T Cai","year":"2021","unstructured":"Cai M-T, Zheng Y, Wang S et al (2021) Clinical Relevance of Cerebrospinal Fluid Antibody Titers in Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Brain Sci 12:4. https:\/\/doi.org\/10.3390\/brainsci12010004","journal-title":"Brain Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07642-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:05:12Z","timestamp":1728691512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["7642"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07642-1","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tim J von Oertzen has received payment or honoraria for lectures, presentations, or manuscript writing support from Angelini Pharma, Eisai, GW Pharmaceuticals, Jazz Pharma, Livanova, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, GW Pharmaceuticals, Jazz Pharma, and Zogenix Pharma outside the submitted work. Judith Wagner has received payment or honoraria for lectures, presentations, or travel grants from Boehringer Ingelheim, Janssen-Cilag GmbH, Pfizer Pharma GmbH, Novartis Pharma GmbH, Roche Austria GmbH, and UCB Pharma AG and has served on advisory boards for Janssen-Cilag GmbH and Novartis Pharma GmbH outside the submitted work. Eva Soellradl reports no conflicts of interest.Research involving human participants and informed consent.This research involves a retrospective analysis of patient data. It was approved by the Ethics Committee of Upper Austria. Informed consent was waived due to the retrospective character.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}